SCLP vs. FARN, FUM, POLB, ETX, 4BB, TRX, AREC, REDX, SAR, and C4XD
Should you be buying Scancell stock or one of its competitors? The main competitors of Scancell include Faron Pharmaceuticals Oy (FARN), Futura Medical (FUM), Poolbeg Pharma (POLB), e-therapeutics (ETX), 4basebio (4BB), Tissue Regenix Group (TRX), Arecor Therapeutics (AREC), Redx Pharma (REDX), Sareum (SAR), and C4X Discovery (C4XD). These companies are all part of the "biotechnology" industry.
Faron Pharmaceuticals Oy (LON:FARN) and Scancell (LON:SCLP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings, institutional ownership and community ranking.
In the previous week, Scancell's average media sentiment score of 0.00 equaled Faron Pharmaceuticals Oy'saverage media sentiment score.
13.2% of Faron Pharmaceuticals Oy shares are owned by institutional investors. Comparatively, 45.7% of Scancell shares are owned by institutional investors. 41.8% of Faron Pharmaceuticals Oy shares are owned by company insiders. Comparatively, 5.7% of Scancell shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Scancell's return on equity of 0.00% beat Faron Pharmaceuticals Oy's return on equity.
Faron Pharmaceuticals Oy has a beta of -0.14, suggesting that its share price is 114% less volatile than the S&P 500. Comparatively, Scancell has a beta of 0.34, suggesting that its share price is 66% less volatile than the S&P 500.
Faron Pharmaceuticals Oy received 130 more outperform votes than Scancell when rated by MarketBeat users. Likewise, 77.51% of users gave Faron Pharmaceuticals Oy an outperform vote while only 74.50% of users gave Scancell an outperform vote.
Scancell has higher revenue and earnings than Faron Pharmaceuticals Oy. Scancell is trading at a lower price-to-earnings ratio than Faron Pharmaceuticals Oy, indicating that it is currently the more affordable of the two stocks.
Summary
Scancell beats Faron Pharmaceuticals Oy on 7 of the 12 factors compared between the two stocks.
Get Scancell News Delivered to You Automatically
Sign up to receive the latest news and ratings for SCLP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SCLP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Scancell Competitors List
Related Companies and Tools
